Our company is actively upgrading culture media for Mycoplasma sanguineum (M.s.), Mycoplasma orale (M.o.), and Mycoplasma hyorhinis (M.h.), based on the standards of the Japanese Pharmacopoeia (JP) and United States Pharmacopeia (USP). These upgrades aim to achieve high sensitivity and reproducibility for these difficult-to-culture mycoplasma species, enabling more accurate and reliable microbiological testing.
We are committed to meeting the strict standards of the pharmaceutical industry by delivering culture media of consistently high quality. Through continuous technological innovation and reinforced quality control, we ensure our products comply with various international regulations.
This ongoing effort will further enhance industry trust and strengthen our global competitiveness.